Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Jul. 16, 2012, 10:59 AM
    Johnson & Johnson (JNJ): Declares $0.61/share quarterly dividend, in line with previous. Forward yield 3.6%. For shareholders of record Aug 28; Payable Sep 11; ex-div date Aug 24. (PR)
    | Jul. 16, 2012, 10:59 AM | Comment!
  • Jul. 12, 2012, 6:06 AM
    J&J (JNJ) could face a bill of almost $4.8B to cover revision surgery for its Pinnacle metal-on-metal hip system, estimates attorney Brian Devine, who is handling cases in which the device has failed. That would add to the $3B J&J has shelled out following the recall of its ASR all-metal artificial hips two years ago.
    | Jul. 12, 2012, 6:06 AM | Comment!
  • Jul. 9, 2012, 8:40 AM
    The FDA grants priority review to Bayer's (BAYRY.PK) and J&J's (JNJ) blood-clotting treatment Xarelto for use against deep vein thrombosis and pulmonary embolism, and the prevention of venous thromboembolism in people who have already had it. However, Bayer withdraws its request to use Xarelto to lower the risk of blood clots in heart-stent patients.
    | Jul. 9, 2012, 8:40 AM | Comment!
  • Jul. 8, 2012, 7:41 AM
    Seven DJIA components have hit all-time highs this year (vs. 8 in 2011), with JNJ and AXP seemingly next in line. Many of the blue chips boast strong balance sheets, consistent cash flows, and yields matching or beating Treasurys - adaptive managements are thrown in for free. What's not to like?
    | Jul. 8, 2012, 7:41 AM | 21 Comments
  • Jul. 2, 2012, 12:16 PM
    J&J (JNJ +0.4%) is seeking accelerated FDA approval for bedaquiline, the first new type of drug to treat tuberculosis in over four decades, and the first for specifically fighting the increasingly common strain of the disease that is resistant to multiple drugs. J&J filing is supported by data from a Phase II trial. (PR)
    | Jul. 2, 2012, 12:16 PM | Comment!
  • Jun. 28, 2012, 10:53 AM
    Pharmaceutical stocks are down following the Supreme Court healthcare opinion, although not dramatically: AZN -0.4%, GSK -1.6%, SNY -0.8%, PFE -0.8%, ABT -0.8%, MRK -0.7%, LLY -1%, WPI -0.9%, NVS -0.7%, JNJ -0.4%. iShares Dow Jones US Healthcare ETF (IYH) -0.95%, the Health Care SPDR (XLV) is -1.3%.
    | Jun. 28, 2012, 10:53 AM | 2 Comments
  • Jun. 25, 2012, 2:58 PM
    The FDA will convene an advisory panel meeting this week to discuss metal-on-metal hip implants made by Johnson & Johnson (JNJ -0.2%) and Zimmer Holding (ZMH -1.8%), which have been the subject of thousands of patient lawsuits. The metal devices have been linked to almost 16,800 adverse events in the U.S. between 2000 and 2011, according regulators, and need more consistent testing to help lower high failure rates that lead to risky replacement surgeries. (draft report)
    | Jun. 25, 2012, 2:58 PM | Comment!
  • Jun. 22, 2012, 1:55 PM
    Johnson & Johnson (JNJ +0.4%) receives a favorable Barron's write-up. The paper talks up J&J's 3.7% dividend yield, low P/E, diverse product line, and new drug launches, along with its recently-closed acquisition of medical device maker Synthes. (earlier)
    | Jun. 22, 2012, 1:55 PM | Comment!
  • Jun. 22, 2012, 5:00 AM
    The FDA has blocked J&J's (JNJ) application to widen the use of its Xarelto blood thinner to prevent heart attacks and strokes in people with acute coronary syndrome, a market estimated at $1B. J&J said it will work with the FDA to address their questions, indicating it hasn't given up hope of eventually getting the authorization.
    | Jun. 22, 2012, 5:00 AM | 3 Comments
  • Jun. 20, 2012, 7:20 PM
    Johnson & Johnson (JNJ) says it's close to settling a DoJ probe into the off-label marketing of its antipsychotic medication Risperdal. The settlement is expected to be one of the largest for a drug-marketing case, as JNJ and the government discuss a payment of $1.5B - $2B or higher.
    | Jun. 20, 2012, 7:20 PM | 3 Comments
  • Jun. 15, 2012, 6:10 PM
    Shares of orthopedics stocks rose today after privately held Biomet said FQ4 sales rose 3.4%. Industry sales have been weak as people delay hip and knee replacement surgeries in the weak economy. Biomet, which reports earlier than peers, is viewed as an indicator for the rest of the industry. The news boosted ZMH +4.2%, SYK +3.5%, WMGI +1.8%, JNJ +0.9%.
    | Jun. 15, 2012, 6:10 PM | 1 Comment
  • Jun. 13, 2012, 9:20 AM
    J&J (JNJ) +1.5% as it receives a trio of upgrades, including one from JPM for the first time in four years. The bank raises J&J to to "overweight" from "neutral," citing the company's recently launched cancer, hepatitis and HIV drugs. Meanwhile, Jefferies increases J&J to "buy" and Raymond James to "outperform." (see also)
    | Jun. 13, 2012, 9:20 AM | Comment!
  • Jun. 13, 2012, 2:44 AM
    U.S. regulators cleared J&J's (JNJ) $19.7B purchase of Synthes. The transaction will close tomorrow. A J&J subsidiary initiated ~$12.9B in accelerated buyback agreements to help finance the cash-and-stock acquisition. The Synthes deal will add $0.03-0.05 to 2012 EPS, a turnaround from prior forecast of a $0.22/share reduction. In 2013, it will add $0.10-0.15 to EPS, ex-certain items.
    | Jun. 13, 2012, 2:44 AM | 1 Comment
  • Jun. 12, 2012, 11:41 AM
    These 20 stocks will do well no matter what, UBS says: SUN, KMI, NUE, MWV, MAS, IRM, WYNN, LEG, RAI, MO, BMY, JNJ, CINF, PBCT, SAI, PAYX, FTR, WIN, PGN, POM. These stocks boast strong dividend payouts, and "tend to provide the most consistent alpha without the need for more tactical management."
    | Jun. 12, 2012, 11:41 AM | 9 Comments
  • Jun. 11, 2012, 4:29 PM
    Johnson & Johnson (JNJ) has won FTC approval to acquire Swiss medical device maker Synthes, more than a year after the deal was first announced. In exchange for the go-ahead, J&J promises to sell a product used to treat serious wrist fractures and other assets to Biomet. The EU approved the acquisition in April following a pledge by J&J to sell its trauma ops in the region. (earlier)
    | Jun. 11, 2012, 4:29 PM | Comment!
  • Jun. 11, 2012, 5:35 AM
    J&J (JNJ) may announce this week that it has agreed to pay up to $2.2B to settle investigations into how it marketed its Risperdal antipsychotic treatment and other drugs, and claims it paid kickbacks to Omnicare (OCR), Bloomberg reports. The company will make a misdemeanor plea, with the deal including a criminal penalty of as much as $600M.
    | Jun. 11, 2012, 5:35 AM | 3 Comments
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.